Phytoestrogens and other botanicals: On the problems of evidence-based evaluation

Recent Patents on Cardiovascular Drug Discovery

Volumn 8, Issue 1, 2013, Pages 67-71

  Jargin, Sergei V ^a  

^a PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

Author keywords

Atherosclerosis; Evidence based medicine; Menopause; Phytoestrogens; Placebo; Soybean

Indexed keywords

HORMONE; PHYTOESTROGEN;

AGRICULTURE; ARTIFICIAL MILK; ATHEROSCLEROSIS; BIOASSAY; ESTROGEN DEFICIENCY; EVIDENCE BASED PRACTICE; FEMALE FERTILITY; FOOD INTAKE; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HUMAN; MALE FERTILITY; MENOPAUSAL SYNDROME; PARENTERAL NUTRITION; PRIORITY JOURNAL; REVIEW; VEGETABLE;

ANIMALS; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; PATENTS AS TOPIC; PHYTOESTROGENS; PHYTOTHERAPY; PLANT PREPARATIONS; PLANTS, MEDICINAL; SOYBEANS;

EID: 84878755901     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/18722083113079990009     Document Type: Review

References (69)

1. Patisaul HB, Jefferson W. The pros and cons of phytoestrogens. Front Neuroendocrinol 2010; 31: 400-419.
2. Barnes S. The biochemistry, chemistry and physiology of the isoflavones in soybeans and their food products. Lymphat Res Biol 2010; 8:89-98.
3. Nestel PJ, Pomeroy S, Kay S, Komesaroff P, Behrsing J, Cameron JD, et al. Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J Clin Endocrinol Metab 1999; 84: 895-898.
4. Cederroth CR, Zimmermann C, Nef S. Soy, phytoestrogens and their impact on reproductive health. Mol Cell Endocrinol 2012; 355: 192-200.
5. Baber R. Phytoestrogens and post reproductive health. Maturitas 2010; 66: 344-349.
6. Gencel VB, Benjamin MM, Bahou SN, Khalil RA. Vascular effects of phytoestrogens and alternative menopausal hormone therapy in cardiovascular disease. Mini Rev Med Chem 2012; 12: 149-174.
7. Taku K, Melby MK, Kronenberg F, Kurzer MS, Messina M. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: Systematic review and meta-analysis of randomized controlled trials. Menopause 2012; 19: 776-790.
8. Gold EB, Leung K, Crawford SL, Huang MH, Waetjen LE, Greendale GA. Phytoestrogen and fiber intakes in relation to incident vasomotor symptoms: results from the Study of Women's Health Across the Nation. Menopause 2013; 20: 305-314.
9. Lethaby AE, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2007; (4): CD001395.
10. Krebs EE, Ensrud KE, MacDonald R, Wilt TJ. Phytoestrogens for treatment of menopausal symptoms: A systematic review. Obstet Gynecol 2004; 104: 824-836.
11. Cheema D, Coomarasamy A, El-Toukhy T. Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidencebased review. Arch Gynecol Obstet 2007; 276: 463-469.
12. Al-Azzawi F, Wahab M. Effectiveness of phytoestrogens in climacteric medicine. Ann N Y Acad Sci 2010; 1205: 262-267.
13. Villaseca P. Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: What needs to be known for practice. Climacteric 2012; 15: 115-124.
14. Speroff L. Alternative therapies for postmenopausal women. Int J Fertil Womens Med 2005; 50: 101-114.
15. Sirtori CR, Arnoldi A, Johnson SK. Phytoestrogens: end of a tale? Ann Med 2005; 37: 423-438.
16. Davis SR. Phytoestrogen therapy for menopausal symptoms? BMJ 2001; 323: 354-355.
17. Coxam V. Phyto-oestrogens and bone health. Proc Nutr Soc 2008; 67: 184-195.
18. This P, de Cremoux P, Leclercq G, Jacquot Y. A critical view of the effects of phytoestrogens on hot flashes and breast cancer risk. Maturitas 2011; 70: 222-226.
19. Haimov-Kochman R, Brzezinski A, Hochner-Celnikier D. Herbal remedies for menopausal symptoms: are we cautious enough? Eur J Contracept Reprod Health Care 2008; 13: 133-137.
20. Wilson S, Blaschek K, de Mejia E. Allergenic proteins in soybean: processing and reduction of P34 allergenicity. Nutr Rev 2005; 63: 47-58.
21. de Villiers TJ, Bagratee JS, Dalmeyer JP, Davey MR, Davis CP, Guidozzi F, et al. South African Menopause Society Council revised consensus position statement on menopausal hormone therapy. S Afr Med J 2007; 97: 354-357.
22. Jargin SV. Letter to the Editor. Menopause 2013; 20: 359.
23. Wuttke W, Jarry H, Seidlová-Wuttke D. Isoflavones - safe food additives or dangerous drugs? Ageing Res Rev 2007; 6: 150-188.
24. Leclercq G, de Cremoux P, This P, Jacquot Y. Lack of sufficient information on the specificity and selectivity of commercial phytoestrogens preparations for therapeutic purposes. Maturitas 2011; 68: 56-64.
25. Usui T. Pharmaceutical prospects of phytoestrogens. Endocr J 2006; 53: 7-20
26. Setchell KD, Clerici C. Equol: history, chemistry, and formation. J Nutr 2010; 140: 1355S-1362S.
27. Adgent MA, Daniels JL, Edwards LJ, Siega-Riz AM, Rogan WJ. Early-life soy exposure and gender-role play behavior in children. Environ Health Perspect 2011; 119: 1811-1816.
28. Martinez J, Lewi JE. An unusual case of gynecomastia associated with soy product consumption. Endocr Pract 2008; 14: 415-418.
29. Jefferson WN, Williams CJ. Circulating levels of genistein in the neonate, apart from dose and route, predict future adverse female reproductive outcomes. Reprod Toxicol 2011; 31: 272-279.
30. Whitten PL, Lewis C, Russell E, Naftolin F. Potential adverse effects of phytoestrogens. J Nutr 1995; 125: 771S-776S.
31. Messina M, Melby MK, Kronenberg F, Kurzer MS, Taku K. Letter to the editor. Menopause 2013; 20: 359-361.
32. Saayman BD. The use of alternative lipid emulsions in paediatric and neonatal parenteral nutrition. S Afr J Clin Nutr 2011; 24: S32-S34.
33. Messina M. Soybean isoflavone exposure does not have feminizing effects on men: a critical examination of the clinical evidence. Fertil Steril 2010; 93: 2095-2104.
34. Jargin SV. Health care and life expectancy: A letter from Russia. Public Health 2013; 127: 189-190.
35. Adlercreutz H. Epidemiology of phytoestrogens. Baillieres Clin Endocrinol Metab 1998; 12: 605-623.
36. Bingham SA, Atkinson C, Liggins J, Bluck L, Coward A. Phytooestrogens: where are we now? Br J Nutr 1998;79: 393-406.
37. Sukmanskii OI. Isoflavones and calcified tissues. Usp Fiziol Nauk 2002; 33(2): 83-94.
38. Tutel'ian VA, Pavliuchkova MS, Pogozheva AV, Derbeneva SA. Use of phytoestrogens in medicine. Vopr Pitan 2003; 72(2): 48-54.
39. Lipworth L, Adami HO, Trichopoulos D, Carlström K, Mantzoros C. Serum steroid hormone levels, sex hormone-binding globulin, and body mass index in the etiology of postmenopausal breast cancer. Epidemiology 1996; 7: 96-100.
40. Smetnik VP. Medicine of climacterium. Yaroslavl: Litera, 2006.
41. Nikitina NA, Sobenin IA, Myasoedova VA, Korennaya VV, Mel'nichenko AA, Khalilov EM, et al. Antiatherogenic effect of grape flavonoids in an ex vivo model. Bull Exp Biol Med 2006; 141: 712-715.
42. Orekhov AN, Sobenin IA, Korneev NV, Kirichenko TV, Myasoedova VA, Melnichenko AA, et al. Anti-Atherosclerotic Therapy Based on Botanicals. Recent Pat Cardiovasc Drug Discov 2012 PRC-EPUB-20121123-1
43. Orekhov, A.N., Sobenin, I.A., Kirichenko, T.V., Myasoedova, V.A., Mel'nichenko, A.A., Orekhova, V.A. Method of atherosclerosis prevention and treatment. RU2455016 (2011).
44. Gorchakova TV, Myasoedova VA, Sobenin IA, Orekhov AN. The reduction of serum atherogenicity by natural anti-inflammatory drugs. Abstracts of the XIV International Symposium on Atherosclerosis, 18-22 June 2006, Rome. Atherosclerosis Supplements 2006; 7(3): 230.
45. Korennaya VV, Myasoedova VA, Nikitina NA, Sobenin IA, Orekhov AN Bioflavonoid-rich botanicals reduce blood serum atherogenicity in perimenopausal women. Abstracts of the XIV International Symposium on Atherosclerosis, 18-22 June 2006, Rome. Atherosclerosis Supplements 2006; 7(3): 444.
46. Jargin SV. Testing of serum atherogenicity in cell cultures: questionable data published. Ger Med Sci 2012; 10: Doc02.
47. Chazov EI, Tertov VV, Orekhov AN, Lyakishev AA, Perova NV, Kurdanov KA, et al. Atherogenicity of blood serum from patients with coronary heart disease. Lancet 1986; 2: 595-8.
48. Aksenov D, Orekhova V, Kireev R, Andrianova I, Smirnov A, Sobenin I, et al. Effect of sex hormones on intracellular cholesterol accumulation and LDL aggregation. Abstracts of the 77th Congress of the European Atherosclerosis Society, 26-29 April 2008, Istanbul. Atherosclerosis Supplements 2008; 9(1): 20.
49. Kireev RA, Kuvshinova E, Andrianova IV, Sobenin IA, Orekhov AN. Effect of sex hormones on atherosclerotic indices in primary culture of female cells. Abstracts of the XIV International Symposium on Atherosclerosis, 18-22 June 2006, Rome. Atherosclerosis Supplements 2006; 7(3): 250.
50. Orekhov AN, Sobenin IA. Serum atherogenicity predicts the progression of atherosclerosis. Abstracts of the XIV International Symposium on Atherosclerosis, 18-22 June 2006, Rome. Atherosclerosis Supplements 2006; 7(3): 209.
51. Panosian, A.G., Orekhov, A.N. Anti-atherosclerotic and antiatherogenic drug. RU2051673 (1992).
52. Orekhov AN, Tertov VV, Pokrovsky SN, Adamova IY, Martsenyuk ON, Lyakishev AA, et al. Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low-density lipoproteins and an approach to its elimination. Circ Res 1988; 62: 421-429.
53. Tertov VV, Orekhov AN, Sobenin IA, Gabbasov ZA, Popov EG, Yaroslavov AA, et al. Three types of naturally occurring modified lipoproteins induce intracellular lipid accumulation due to lipoprotein aggregation. Circ Res 1992; 71: 218-228.
54. Tertov VV, Orekhov AN, Martsenyuk ON, Perova NV, Smirnov VN. Low-density lipoproteins isolated from the blood of patients with coronary heart disease induce the accumulation of lipids in human aortic cells. Exp Mol Pathol 1989; 50: 337-347.
55. Orekhov AN, Baldenkov GN, Tertov VV, Ryong LH, Kozlov SG, Lyakishev AA, et al. Cardiovascular drugs and atherosclerosis: Effects of calcium antagonists, beta-blockers, and nitrates on atherosclerotic characteristics of human aortic cells. J Cardiovasc Pharmacol 1988; 12 Suppl 6: S66-S68.
56. Orekhov AN, Tertov VV, Sobenin IA, Pivovarova EM. Direct antiatherosclerosis- related effects of garlic. Ann Med 1995; 27: 63-65.
57. Orekhov AN, Kosykh VA, Repin VS, Smirnov VN. Cell proliferation in normal and atherosclerotic human aorta. II. Autoradiographic observation on deoxyribonucleic acid synthesis in primary cell culture. Lab Invest 1983; 48: 749-754.
58. Orekhov AN, Tertov VV, Kudryashov SA, Khashimov KhA, Smirnov VN. Primary culture of human aortic intima cells as a model for testing antiatherosclerotic drugs. Effects of cyclic AMP, prostaglandins, calcium antagonists, antioxidants, and lipidlowering agents. Atherosclerosis 1986; 60: 101-110.
59. Shagaeva MM, Slavina LS, Balabolkin MI, Sobenin IA, Orekhov AN. Effect of squid liver fat and krill meat on blood serum atherogenicity in patients with type I diabetes mellitus. Probl Endokrinol (Mosk) 1993; 39: 21-23.
60. Ryong LH, Tertov VV, Vasil'ev AV, Tutel'yan VA, Orekhov AN. Antiatherogenic and antiatherosclerotic effects of mushroom extracts revealed in human aortic intima cell culture. Drug Dev Res 1989; 17: 109-117.
61. Orekhov AN, Kalenich OS, Tertov VV, Perova NV, Novikov IyD, Lyakishev AA, et al. Diagnostic value of immune cholesterol as a marker for atherosclerosis. J Cardiovasc Risk 1995; 2: 459-466.
62. Tertov VV, Orekhov AN, Sayadyan KS, Serebrennikov SG, Kacharava AG, Lyakishev AA, et al. Correlation between cholesterol content in circulating immune complexes and atherogenic properties of CHD patients' serum manifested in cell culture. Atherosclerosis 1990; 81: 183-189.
63. Kacharava AG, Tertov VV, Orekhov AN. Autoantibodies against low-density lipoprotein and atherogenic potential of blood. Ann Med 1993; 25: 551-555.
64. Sobenin IA, Chistiakov DA, Bobryshev YV, Orekhov AN. Blood atherogenicity as a target for anti-atherosclerotic therapy. Curr Pharm Des 2013 Feb 15. [Epub ahead of print]
65. Orekhov AN. Direct anti-atherosclerotic therapy; development of natural anti-atherosclerotic drugs preventing cellular cholesterol retention. Curr Pharm Des 2013 Feb 15. [Epub ahead of print]
66. Virella G, Lopes-Virella MF. Atherogenesis and the humoral immune response to modified lipoproteins. Atherosclerosis 2008; 200: 239-246.
67. Jargin SV, Wilson DW. Some pitfalls in testing anti-atherogenic agents in cell cultures. World Heart J 2013 (in press).
68. Jargin SV. On the scientific misconduct: a letter from Russia. Einstein (São Paulo) 2013 (in press).
69. Jargin SV. Discussion of Evaluation of cholesterol-lowering and antioxidant properties of sugar cane policosanols in hamsters and humans. Appl Physiol Nutr Metab 2009; 34: 75, discussion 76-7.